Skip to main content
Premium Trial:

Request an Annual Quote

Former Gemini CEO Paul Kelly Takes Helm at Orchid

NEW YORK, May 28 - Orchid Biosciences has appointed Paul Kelly as its new CEO, filling a position left vacant when Dale Pfost left in December 2002, the company announced today.


Kelly, 43, is an Australian-born endocrinologist and the former CEO of Gemini Genomics, which he co-founded in 1995. Gemini, a clinical genomics company that collected genetic, clinical, and environmental data from different human populations and analyzed this data to look for drug targets, merged with Sequenom in 2001.


Since leaving Gemini, Kelly founded Nanovis, a materials science company, and AgaMatrix, a medical devices  company. He most recently held the CEO post at data analysis company OmniViz.


"We believe that Paul has the right mix of vision and hands-on expertise in the commercialization of clinical genetics, genoprofiling and research services for the biomedical and biotechnology sectors to take Orchid to its next stage of growth," said George Poste, chairman of Orchid, in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.